Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,628,906
  • Shares Outstanding, K 78,684
  • Annual Sales, $ 33,050 K
  • Annual Income, $ -267,890 K
  • 60-Month Beta 1.84
  • Price/Sales 109.03
  • Price/Cash Flow N/A
  • Price/Book 4.22
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 81.58% ( +7.05%)
  • Historical Volatility 61.50%
  • IV Percentile 24%
  • IV Rank 24.60%
  • IV High 116.97% on 06/14/22
  • IV Low 70.03% on 12/17/21
  • Put/Call Vol Ratio 0.49
  • Today's Volume 300
  • Volume Avg (30-Day) 403
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 13,541
  • Open Int (30-Day) 14,559

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.15
  • Number of Estimates 14
  • High Estimate 1.41
  • Low Estimate -1.70
  • Prior Year -1.09
  • Growth Rate Est. (year over year) -5.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.00 +4.82%
on 12/02/22
57.49 -19.78%
on 11/15/22
-4.98 (-9.75%)
since 11/02/22
3-Month
44.00 +4.82%
on 12/02/22
69.28 -33.43%
on 09/15/22
-9.89 (-17.66%)
since 09/02/22
52-Week
37.08 +24.38%
on 06/14/22
130.33 -64.61%
on 12/17/21
-63.83 (-58.05%)
since 12/02/21

Most Recent Stories

More News
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

PBYI : 4.45 (-2.41%)
ITCI : 54.08 (+1.18%)
NTLA : 46.12 (+0.70%)
KOD : 7.46 (+2.33%)
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

AGIO : 31.52 (+7.25%)
PBYI : 4.45 (-2.41%)
NTLA : 46.12 (+0.70%)
KOD : 7.46 (+2.33%)
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

REGN : 766.39 (+0.68%)
PBYI : 4.45 (-2.41%)
NTLA : 46.12 (+0.70%)
KOD : 7.46 (+2.33%)
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

PBYI : 4.45 (-2.41%)
RARE : 40.17 (+6.24%)
NTLA : 46.12 (+0.70%)
KOD : 7.46 (+2.33%)
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

NTLA : 46.12 (+0.70%)
EVGN : 0.6300 (-2.36%)
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

VRTX : 321.37 (+0.19%)
PBYI : 4.45 (-2.41%)
NTLA : 46.12 (+0.70%)
CRSP : 54.50 (+0.29%)
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

RGEN : 186.05 (-1.13%)
PBYI : 4.45 (-2.41%)
NTLA : 46.12 (+0.70%)
KOD : 7.46 (+2.33%)
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABCL : 12.71 (-3.57%)
NTLA : 46.12 (+0.70%)
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NTLA : 46.12 (+0.70%)
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?

Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.

BMRN : 105.56 (+2.47%)
AVEO : 14.92 (-0.07%)
NTLA : 46.12 (+0.70%)
ASRT : 3.06 (+2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 50.71
2nd Resistance Point 48.95
1st Resistance Point 47.53
Last Price 46.12
1st Support Level 44.35
2nd Support Level 42.59
3rd Support Level 41.17

See More

52-Week High 130.33
Fibonacci 61.8% 94.71
Fibonacci 50% 83.71
Fibonacci 38.2% 72.70
Last Price 46.12
52-Week Low 37.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar